Clinical Trials Browser

Phase 1/2 × Ovarian Neoplasms × Temozolomide × Clear all

NCT05417594 2026-03-12

CERTIS1

Phase 1/2 Recruiting

BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Phase 1/2 Completed

BreastGynecologicLymphoidOther hematologic neoplasm

Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Triple Negative Breast Neoplasms

NCT04851834 2022-12-20

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Phase 1/2 Terminated

CNSGenitourinaryGynecologic

Urinary Bladder Neoplasms, Glioma, Ovarian Neoplasms

NCT00005952 2013-06-20

Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors

Phase 1/2 Completed

CNSGenitourinaryGynecologicHead & NeckSarcoma

Familial ependymoma, Testicular Germ Cell Tumor, Astrocytoma, Head and Neck Neoplasms, Kidney Neoplasms, Medulloblastoma, Nasopharyngeal Neoplasms, Wilms Tumor, Neuroblastoma, Oligodendroglioma, Ovarian Neoplasms, Sarcoma, Testicular Neoplasms, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Optic Nerve Glioma